Somatostatin receptor (SSTR)-based imaging and therapy has emerged as well-established modality in neuroendocrinetumors. However, its role in inflammation imaging is still evolving. We present a 48-year-old male with metastatic neuroendocrinetumor who underwent lutetium-177-based somatostatin receptor-based therapy. The post-therapy scan showed afocal tracer uptake in the left calf muscle in addition to the expected tracer uptake at the primary and metastatic sites. Further,cross-sectional imaging and biochemical investigations revealed peripheral vascular disease (PVD). The incidental traceruptake in the calf on post-therapy scan potentiates the role of somatostatin receptor scintigraphy in identifying macrophagespecificinflammatory reactions.